Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
Robin Kate KelleyTim MeyerLorenza RimassaPhilippe MerleJoong-Won ParkThomas YauStephen L ChanJean-Frederic BlancVincent C TamAlbert TranVincenzo DadduzioDavid W MarkbyRajesh KaldateAnn-Lii ChengAnthony B El-KhoueiryGhassan K Abou-AlfaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Cabozantinib improved outcomes versus placebo across a range of baseline AFP levels. On-treatment AFP response and control rates were higher with cabozantinib than placebo, and were associated with longer OS and PFS with cabozantinib.